Skip to main content
PMC home page
Respiratory Research logoLink to Respiratory Research
. 2015 Feb 7;16(1):20. doi: 10.1186/s12931-015-0175-9

A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids

Christian Vogelberg 1,✉, Petra Moroni-Zentgraf 2, Migle Leonaviciute-Klimantaviciene 3, Ralf Sigmund 4, Eckard Hamelmann 5, Michael Engel 2, Stanley Szefler 6
PMCID: PMC4331449  PMID: 25851298

Abstract

Background

A considerable number of children with asthma remain symptomatic despite treatment with inhaled corticosteroids, resulting in significant morbidity, reduced quality of life, increased healthcare costs and lost school days. The aim of our study was to assess the efficacy, safety and tolerability of once-daily tiotropium Respimat® 5 μg, 2.5 μg and 1.25 μg add-on to medium-dose inhaled corticosteroids, with or without a leukotriene modifier, in children aged 6–11 years with symptomatic asthma.

Methods

In this Phase II, double-blind, placebo-controlled, incomplete-crossover, dose-ranging study, patients were randomised to receive three of the four treatments evaluated: once-daily tiotropium Respimat® 5 μg, 2.5 μg or 1.25 μg or placebo Respimat®, in the evening during the 12-week (three × 4-week) treatment period.

Results

In total, 76, 74, 75 and 76 patients aged 6–11 years received tiotropium Respimat® 5 μg, 2.5 μg, 1.25 μg and placebo Respimat®, respectively. For the primary end point (peak forced expiratory volume in 1 second measured within 3 hours post-dosing), the adjusted mean responses with tiotropium Respimat® 5 μg (272 mL), 2.5 μg (290 mL) and 1.25 μg (261 mL) were significantly greater than with placebo Respimat® (185 mL; p = 0.0002, p < 0.0001 and p = 0.0011, respectively). The safety and tolerability of all doses of tiotropium Respimat® were comparable with those of placebo Respimat®, with no serious adverse events and no events leading to discontinuation.

Conclusions

Tiotropium Respimat® add-on to medium-dose inhaled corticosteroids, with or without a leukotriene modifier, was efficacious in paediatric patients with symptomatic asthma and had comparable safety and tolerability with placebo Respimat®.

Trial registration

ClinicalTrials.gov identifier NCT01383499

Electronic supplementary material

The online version of this article (doi:10.1186/s12931-015-0175-9) contains supplementary material, which is available to authorized users.

Keywords: Asthma, Asthma control, Children, Once-daily, Tiotropium, Lung function, Paediatric, Respimat®

Background

Asthma is a leading cause of childhood morbidity [1]. In the USA alone, around 7 million children and adolescents suffer from asthma [2], and in the UK, one in every seven children aged 2–15 years has asthma symptoms requiring regular treatment [3]. As in adults, a considerable proportion of asthma in children is inadequately controlled by inhaled corticosteroid (ICS) guideline therapy, which represents a significant healthcare concern [4]. In addition to the negative impact on patients’ quality of life, this considerably increases their risk of future exacerbations, with associated increased requirement for healthcare utilisation and costs [5-7]. Data for the USA show that in 2011, 56% of children with asthma suffered an attack [2], with almost 20% visiting an emergency department [8].

While the goals of treatment for children with asthma [9,10] are broadly the same as for adults (to improve control, reduce exacerbations, reduce rescue medication usage, reduce hospitalisations and allow maximum possible participation in normal daily activities), treatment can be complicated by issues that are specific to, or more pronounced in, this age group. Adherence to asthma medication is notably poor in children and adolescents [11], and compliance with twice-daily ICS treatment regimens may be sub-optimal, particularly during asymptomatic periods. In addition, the detection and appropriate management of children with poor asthma control is hampered by the fact that both the affected children and their parents tend to underestimate their asthma severity [5,6,11-14].

Given the prevalence of uncontrolled asthma in children and its health, educational and financial impact, there is clearly a need to further improve asthma control and prevent exacerbations in this population; the long-acting anticholinergic bronchodilator tiotropium represents a potential add-on therapy for such patients [15,16]. Tiotropium has demonstrated efficacy in the treatment of asthma in adults [17-21] and adolescents [22]. Here we report data from the first assessment of tiotropium treatment in children aged 6–11 years with symptomatic asthma. This study evaluated the efficacy, safety and tolerability of three doses of tiotropium in children with symptomatic asthma despite maintenance treatment with ICS.

Methods

Study design

This Phase II, randomised, double-blind, placebo-controlled, incomplete-crossover, dose-ranging study was conducted at 24 centres in six countries from 23 August 2011 to 25 September 2012. The study met all local legal and regulatory requirements and conformed to the Declaration of Helsinki and to Good Clinical Practice and Good Publication Practice guidelines. The protocol was approved by an independent ethics committee at each study centre, and all patients and their parents or legal guardians provided written, informed consent.

Following a 4-week run-in period, during which patients received ICS maintenance therapy with or without a leukotriene modifier, patients were randomised in a 1:1:1:1 ratio to receive once-daily tiotropium 5 μg, 2.5 μg, 1.25 μg or placebo, all delivered via the Respimat® SoftMist™ inhaler (Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany), during three 4-week treatment periods. Patients received three of the four available treatments with no washout between treatment periods (Figure 1) as pharmacodynamic steady state with tiotropium is known to be achieved after 3 weeks in patients with chronic obstructive pulmonary disease [23,24]. All study treatments (tiotropium Respimat® 5 μg, 2.5 μg, 1.25 μg and placebo Respimat®) were self-administered, under parental supervision every evening, double-blind as add-on to maintenance treatment with medium-dose ICS (200–400 μg budesonide or equivalent dose), with or without a leukotriene modifier. Patients and parents received training on the use of the Respimat® SoftMist™ inhaler at Visits 1 (screening) and 2 (randomisation), and at later visits if required. Blinding was maintained up to database lock. Rescue medication (open-label salbutamol inhaler, 100 μg per puff) was permitted during screening and the entire treatment period. The use of antibiotics was not restricted during the trial; temporary increases in the dose of ICS or addition of systemic steroids was permitted as well as the addition of short-acting theophylline preparations for the treatment of acute exacerbations.

Figure 1.

Figure 1

Open in a new tab

Study design. FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroids; PEF, peak expiratory flow; QD, once-daily.

A fixed block randomisation was used to ensure that a balanced number of patients was allocated to each treatment. The order of patient assignment to treatment sequences was randomised. The randomisation list was generated by Boehringer Ingelheim using a validated system with a pseudo-random number generator and supplied seed number.

Study population

Male and female patients aged 6–11 years with a ≥6-month history of asthma and diagnosis confirmed at screening were eligible for enrolment into this study. All patients were required to have bronchodilator reversibility resulting in a forced expiratory volume in 1 second (FEV1) increase of ≥12% within 15–30 minutes after the administration of 200 μg salbutamol, and to be symptomatic at screening and prior to randomisation, as defined by a seven-question Asthma Control Questionnaire (ACQ-7) mean score of ≥1.5. All patients received maintenance therapy with ICS at a stable medium dose (200–400 μg budesonide or equivalent dose) either as monotherapy or in combination with a long-acting β2-agonist (LABA) or leukotriene modifier for ≥4 weeks prior to screening (LABAs had to be stopped at least 24 hours prior to screening; however, leukotriene modifiers were permitted throughout the trial). In addition, all patients had to have a pre-bronchodilator FEV1 60–90% of predicted normal at screening and were to demonstrate pre-bronchodilator FEV1 variability at randomisation within ±30% compared with the screening value. Exclusion criteria included a significant medical condition other than asthma, congenital heart disease, any acute asthma exacerbation or acute respiratory tract infection during the 4 weeks prior to screening, and treatment with long-acting inhaled or systemic anticholinergics or systemic (oral or intravenous) corticosteroids within 4 weeks prior to screening.

Study end points

All study end points were assessed as a response, defined as the difference from baseline (randomisation, Visit 2) at the end of each of the three 4-week treatment periods. The primary efficacy end point was peak FEV1 within 3 hours post-dosing (peak FEV1(0–3h)). Secondary end points included trough FEV1, FEV1 area under the curve within 3 hours post-dosing (AUC(0–3h)), peak forced vital capacity within 3 hours post-dosing (FVC(0–3h)), trough FVC, FVC AUC(0–3h) and pre-dose morning and evening peak expiratory flow (PEF). Additional end points included individual FEV1 measurements over 3 hours post-dosing and mean forced expiratory flow 25–75% of the FVC at 4 weeks. ACQ-7 and Standardised Paediatric Asthma Quality of Life Questionnaire (PAQLQ[S]) were used to assess asthma control and quality of life, respectively.

Assessments

Lung function assessments were performed and vital signs assessed at Visits 1–5. Lung function assessments were performed at 30 minutes, 1 hour, 2 hours and 3 hours after inhalation of study medication at screening, at the end of the 4-week run-in period and at the end of each 4-week treatment period. Patients recorded twice-daily PEF values and details of asthma symptoms, quality of life and use of rescue medication using the Asthma Monitor® AM3® device (Care Fusion, Höchberg, Germany), combining an electronic peak flow meter and electronic diary, which were reviewed by the investigator at the start of each clinic visit. Mean PEF measurements were determined in the last week of each treatment period to avoid carry-over of previous treatment effects. ACQ-7 and PAQLQ(S) data were collected during Visits 1–5 and 2–5, respectively. Adverse events (AEs) were recorded at every visit.

Statistical analyses

Assuming a standard deviation of 280 mL for within-patient differences in peak FEV1(0–3h), a sample size of 64 completer patients would be required using a full crossover design to detect a treatment difference of 100 mL for peak FEV1(0–3h) based on a two-sample t-test with 80% power and a probability of type I error of 2.5%. Using the equation n = 3*m/2, it was calculated that 96 patients would be required for the incomplete block design used in this study. It was therefore estimated that a sample of approximately 104 patients completing the study would be sufficient for the planned statistical analyses, allowing for a drop-out rate of 8%, as observed in a similar study in adolescent patients [22].

The primary efficacy analysis was performed using the full analysis set, defined as all randomised patients who were treated with at least one dose of study medication, had baseline data and had at least one on-treatment efficacy measurement after a 4-week treatment period. Superiority of treatment with tiotropium Respimat® over placebo Respimat® was tested in a sequential hierarchical fashion at the level of α = 0.025 (one-sided) using a mixed model repeated measures analysis, with ‘treatment’ and ‘period’ as fixed effects and ‘patient’ as a random effect. The study baseline value for the end point was included in the statistical model as a covariate. Adjusted mean values, treatment contrasts, 95% confidence intervals and p values were calculated. Secondary end points were also analysed using the full analysis set and a mixed model repeated measures analysis. The treated set was used for evaluation of safety and was defined as all randomised patients who received at least one dose of study medication.

Results

In total, 101 patients were randomised to receive study treatment. Seventy-six patients received tiotropium Respimat® 5 μg, 74 received tiotropium Respimat® 2.5 μg, 75 received tiotropium Respimat® 1.25 μg and 76 received placebo Respimat® (Additional file 1: Figure S1). One hundred patients completed all three treatment periods, with one patient discontinuing from the study prematurely (consent withdrawn for non-AE-related reasons during the first 4-week treatment period while receiving tiotropium Respimat® 5 μg); this patient was excluded from the full analysis set.

Baseline demographics and disease characteristics

Most patients were male (68.3%), with a mean age of 8.8 years and a mean duration of asthma of 4.5 years (Table 1). Only 5.9% of patients had been exposed to household/second-hand smoking. Approximately two-thirds of patients had concomitant diseases at screening (63.4%), the most common being allergic rhinitis (53.5%).

Table 1.

Baseline demographics and disease characteristics (treated set)

Total
Patients, n (%) 101 (100)
  Male 69 (68.3)
  Female 32 (31.7)
Race, n (%)
  White 101 (100)
Age (years), mean ± SD 8.8 ± 1.7
  6–8 years, n (%) 37 (36.6)
  9–11 years, n (%) 64 (63.4)
Weight (kg), mean ± SD 34.2 ± 10.5
Height (cm), mean ± SD 138.9 ± 12.2
BMI (kg/m2), mean ± SD 17.4 ± 3.2
Smoking exposure, n (%)
  No exposure 95 (94.1)
  Exposure to household/second-hand smoking 6 (5.9)
Duration of asthma (years), mean ± SD 4.5 ± 2.3
  <1 year’s duration, n (%) 6 (5.9)
  1–< 3 years’ duration, n (%) 18 (17.8)
  ≥3 years’ duration, n (%) 77 (76.2)
Open in a new tab

BMI, body mass index; SD, standard deviation.

During the 3 months prior to screening, all patients received treatment with ICS and 36.6% were also treated with a LABA, while 45.5% had taken additional leukotriene modifiers. At the time of randomisation (Visit 2), all patients were taking ICS, with 45.5% of patients also receiving leukotriene modifiers. LABAs were not permitted during the run-in or treatment periods.

Patients’ baseline asthma characteristics are summarised in Table 2. At screening, mean pre- and post-bronchodilator FEV1 values (± standard deviation: 1.539 ± 0.385 L, 1.909 ± 0.469 L) were 79.7% and 98.9% of predicted normal, respectively. Mean reversibility with bronchodilator use (% of pre-bronchodilator) was 370 ± 171 mL (24.6%). At baseline, mean FEV1 was 1.640 ± 0.386 L (85.4% of predicted normal), with 29.7% of patients having an FEV1 value >90% of predicted normal.

Table 2.

Disease characteristics measured during reversibility testing and at baseline (treated set)

Reversibility testing
Pre-bronchodilator a Post-bronchodilator b Baseline pre-dose c
Mean SD Mean SD Mean SD
FEV1
  Predicted normal, L 1.928 0.416
  Actual, L 1.539 0.385 1.909 0.469 1.640 0.386
  Actual, % predicted normal 79.661 8.142 98.908 11.024 85.392 10.711
  Reversibility, mLd 370 171
  Reversibility, % of pre-bronchodilatore 24.578 12.106
  Variation, %f 7.60 12.43
FVC 2.233 0.519
  Predicted normal, L 2.059 0.567 2.341 0.611
  Actual, L 92.266 13.339 105.080 15.560 2.127 0.545
  Actual, % predicted normal 75.830 9.623 82.404 8.817 95.844 15.067
FEV1/FVC, % 78.109 9.467
PEF, L/min 220 56
ICS maintenance dose, μg (budesonide or equivalent dose) 282.2 85.8
Open in a new tab

aMeasured 10 minutes prior to inhalation of two puffs of salbutamol (100 μg per puff) at screening (Visit 1); bMeasured 15–30 minutes after inhalation of two puffs of salbutamol (100 μg per puff) at screening (Visit 1); cMeasured 10 minutes prior to inhalation of study medication at baseline (Visit 2); dCalculated as FEV1 post-bronchodilator – FEV1 pre-bronchodilator; eCalculated as 100 × (FEV1 post-bronchodilator/FEV1 pre-bronchodilator) – 1; fCalculated as 100 × (FEV1 at baseline/pre-bronchodilator FEV1 at screening) – 1. FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroids; PEF, peak expiratory flow; SD, standard deviation.

Efficacy

For the primary efficacy end point, statistically significant differences in peak FEV1(0–3h) response after 4 weeks of treatment were observed for each tiotropium Respimat® dose group versus placebo Respimat® (Figure 2). The adjusted mean differences between tiotropium Respimat® 5 μg, 2.5 μg and 1.25 μg versus placebo Respimat® were 87 mL (p = 0.0002), 104 mL (p < 0.0001) and 75 mL (p = 0.0011), respectively. There was no dose-dependent response observed in patients treated with tiotropium Respimat®, with only minor, non-statistically significant differences between the different doses in peak FEV1(0–3h) response after 4 weeks of treatment.

Figure 2.

Figure 2

Open in a new tab

Peak FEV 1(0–3h) and trough FEV 1 responses after 4 weeks of treatment (full analysis set). Adjusted for ‘treatment’, ‘period’, ‘patient’ and ‘baseline’. *p < 0.05; ***p < 0.001 versus placebo Respimat®. FEV1, forced expiratory volume in 1 second; peak FEV1(0–3h), peak forced expiratory volume in 1 second within 3 hours post-dosing.

Tiotropium Respimat® also improved secondary and additional efficacy end points, including trough FEV1 response, FEV1 AUC(0–3h) response and FEV1 response over 3 hours post-dosing. A statistically significant difference in adjusted mean trough FEV1 response was observed for each tiotropium Respimat® dose group versus placebo Respimat® (Figure 2): 5 μg = 98 mL (p < 0.0001), 2.5 μg = 105 mL (p < 0.0001) and 1.25 μg = 75 mL (p = 0.0023). A statistically significant difference in adjusted mean FEV1 AUC(0–3h) response was also observed for each tiotropium Respimat® dose group versus placebo Respimat® (Figure 3): 5 μg = 91 mL (p < 0.0001), 2.5 μg = 99 mL (p < 0.0001) and 1.25 μg = 68 mL (p = 0.0013). The FEV1 responses with all doses of tiotropium Respimat® were significantly superior to those with placebo Respimat® at all time points up to 3 hours post-dosing (Figure 4).

Figure 3.

Figure 3

Open in a new tab

FEV 1 AUC (0–3h) response after 4 weeks of treatment (full analysis set). Adjusted for ‘treatment’, ‘period’, ‘patient’ and ‘baseline’. *p < 0.05; ***p < 0.001 versus placebo Respimat®. AUC(0–3h), area under the curve within 3 hours post-dosing; FEV1, forced expiratory volume in 1 second.

Figure 4.

Figure 4

Open in a new tab

FEV 1 response over 3 hours post-dosing (full analysis set). FEV1, forced expiratory volume in 1 second.

Although peak FVC(0–3h), trough FVC and FVC AUC(0–3h) responses were improved on tiotropium Respimat® therapy, the improvements were statistically significant only for FVC AUC(0–3h) response with the 2.5 μg dose (p = 0.0383).

Increases from baseline in morning and evening PEF responses were seen after 4 weeks for all tiotropium Respimat® dose groups. A statistically significant improvement in adjusted mean morning PEF response was observed for all three tiotropium Respimat® doses (5 μg = 16 L/min [p = 0.0036], 2.5 μg = 13 L/min [p = 0.0215] and 1.25 μg = 15 L/min [p = 0.0061]), with a statistically significant improvement in adjusted mean evening PEF response of 17 L/min (p = 0.0024) also observed for the 5 μg dose, when compared with placebo Respimat® (Figure 5).

Figure 5.

Figure 5

Open in a new tab

Morning and evening PEF response after 4 weeks of treatment (full analysis set). Adjusted for ‘treatment’, ‘period’, ‘patient’ and ‘baseline’. *p < 0.05 versus placebo Respimat®. PEF, peak expiratory flow.

Statistically significant improvements in adjusted mean forced expiratory flow 25–75% response were observed at all time points up to 3 hours post-dosing for all tiotropium Respimat® dose groups versus placebo Respimat®: 5 μg = 318 mL/sec, 2.5 μg = 319 mL/sec and 1.25 μg = 296 mL/sec at 3 hours post-dosing (all p < 0.0001). No dose-dependent response was observed, and there were no significant differences between the three tiotropium Respimat® dose groups.

Although not statistically significant, numerical improvements in asthma control and quality of life were observed following treatment with tiotropium Respimat®, compared with placebo Respimat® (ACQ-7 adjusted mean response: 5 μg = −0.088, 2.5 μg = −0.120 and 1.25 μg = −0.057; total PAQLQ[S] adjusted mean response: 5 μg = 0.091, 2.5 μg = 0.029 and 1.25 μg = 0.024).

Safety and tolerability

The incidence of AEs experienced while receiving study treatment was comparable across the three tiotropium Respimat® dose groups and the placebo Respimat® treatment group, with events reported for approximately 10% of patients in each group (Table 3). No deaths, serious AEs, AEs leading to discontinuation of study medication, drug-related AEs or pre-specified significant AEs were reported during the study. Only one patient prematurely discontinued study medication, due to consent withdrawal for non-AE-related reasons. All other types of AE were reported in less than 3% of patients and no individual AE was reported in more than two patients in any treatment group.

Table 3.

Adverse events reported by more than one patient in any treatment period (treated set)

Patients, n (%)
Tiotropium Respimat ® 5 μg Tiotropium Respimat ® 2.5 μg Tiotropium Respimat ® 1.25 μg Placebo Respimat ®
(n = 76) (n = 74) (n = 75) (n = 76)
Patients with any adverse event 7 (9.2) 7 (9.5) 7 (9.3) 8 (10.5)
Asthma 2 (2.6) 2 (2.7) 1 (1.3) 1 (1.3)
Bronchitis 2 (2.6) 1 (1.4) 1 (1.3) 1 (1.3)
Headache 1 (1.3) 1 (1.4) 2 (2.7) 0
Nasopharyngitis 0 0 2 (2.7) 2 (2.6)
Pharyngitis 1 (1.3) 1 (1.4) 0 1 (1.3)
Rhinitis 0 2 (2.7) 0 1 (1.3)
Cough 0 0 0 2 (2.6)
Influenza 1 (1.3) 1 (1.4) 0 0
Purulence 0 0 1 (1.3) 0
Respiratory tract infection 0 0 0 1 (1.3)
Urinary tract infection 0 0 0 1 (1.3)
Viral upper respiratory tract infection 1 (1.3) 0 0 0
Stomatitis 0 0 0 1 (1.3)
Chest pain 1 (1.3) 0 0 0
Contusiona 0 0 0 1 (1.3)
Skeletal injury 0 0 0 1 (1.3)
Open in a new tab

aContusion of the lower jaw. Treatment + 30 days.

Discussion

In the present study, once-daily tiotropium Respimat® add-on to medium-dose ICS, with or without a leukotriene modifier, improved lung function in children with symptomatic asthma. For the primary end point, statistically significant improvements in peak FEV1(0–3h) response after 4 weeks of treatment were observed for all tiotropium Respimat® dose groups versus placebo Respimat®.

Analyses of secondary and additional efficacy end points also generally demonstrated the superiority of all tiotropium Respimat® doses tested, with statistically significant improvements in trough FEV1, FEV1 AUC(0–3h) and peak FEV1 at all time points up to 3 hours post-dosing observed with all doses of tiotropium Respimat®, compared with placebo Respimat®. The observed improvements in FVC were generally not significantly different from those observed with placebo Respimat®, which is an expected observation given the age of this patient population.

PEF monitoring is an important tool for measuring airway changes, particularly in patients who may not accurately perceive their worsening symptoms [25]. PEF results, which represent a weekly average of daily values, may provide more reliable data compared with FEV1 measurements, which represent a single value taken on 1 day in a clinic outside of a patient’s real-life setting. Data from the study presented here demonstrate that all doses of tiotropium Respimat® were superior to placebo Respimat® for morning PEF. For evening PEF, which represents a true 24-hour value, the tiotropium Respimat® 5 μg dose also showed superiority when compared with placebo Respimat®, and demonstrated higher values than the 2.5 μg and 1.25 μg doses.

With regard to patient-reported outcomes, a positive trend for improvements in ACQ-7 and PAQLQ(S) scores was observed in this study following treatment with all three doses of tiotropium Respimat®. Additional analyses from parallel-group trials of longer duration and with larger patient numbers are required to further investigate the effect of tiotropium Respimat® on asthma control and quality of life in children with symptomatic asthma.

The study presented here demonstrates that once-daily tiotropium Respimat® add-on to medium-dose ICS, with or without a leukotriene modifier, has safety and tolerability that are comparable with those of placebo Respimat® in children aged 6–11 years with symptomatic asthma. This parallels and further reinforces the data in adult patients, where once-daily tiotropium Respimat® was shown to have similar safety and tolerability when compared with placebo Respimat® in patients with symptomatic asthma on ICS with or without a LABA [20,26,27].

Although the comparison between the tiotropium Respimat® doses was descriptive only, we note that there was no clear dose-dependent response seen for either the primary or any of the secondary or additional efficacy end points. The results of Phase II studies in adult and adolescent patients with asthma have clearly demonstrated a greater response with the 5 μg dose. In these Phase II studies, the once-daily doses of 10 μg, 5 μg, 2.5 μg or 1.25 μg all improved lung function and were well tolerated, with the 5 μg dose achieving the greatest bronchodilation [17,18,22,28]. The long-term clinical efficacy and safety of tiotropium Respimat® 5 μg have been demonstrated in two large Phase III studies in adult patients with symptomatic asthma receiving ICS plus LABA [20].

The Respimat® SoftMist™ inhaler may provide advantages over pressurised metered-dose inhalers and dry-powder inhalers, particularly in the treatment of children with asthma. The increased aerosol production time with the SoftMist™ inhaler may benefit young patients with low inspiratory capacity or poor timing of inhalation to actuation, although correct technique remains important [29]. A single device with once-daily dosing may also improve patient adherence, which is notably poor in children and adolescents [11].

It should be noted that this study has some methodological limitations. The incomplete-crossover design means that all patients did not receive all study treatments; however, this study design reduces inter-patient variability and the number of patients required to reach statistical power, with the lack of washout between treatments promoting patient compliance. The short study duration meant that the focus was on assessment of lung function, and did not allow for a full assessment of asthma symptom control or exacerbation rate.

The data presented in this manuscript encourage and warrant future, large Phase III trials in paediatric patients to confirm these results and to examine the impact of tiotropium Respimat® add-on therapy on long-term efficacy, safety and tolerability. Additional studies will help to determine where tiotropium Respimat® will fit in future treatment guidelines, particularly in relation to high-dose ICS maintenance therapy with or without a LABA.

Conclusion

This first study of tiotropium Respimat® in children with symptomatic asthma has shown that tiotropium Respimat® add-on to medium-dose ICS, with or without a leukotriene modifier, is efficacious and has comparable safety and tolerability with placebo Respimat®. A larger Phase III study is warranted to confirm these promising initial findings.

Acknowledgements

This work was supported by Boehringer Ingelheim. Chih-Lin Li, former statistician for Boehringer Ingelheim, drafted the statistical analysis plan, conducted the statistical analyses and contributed to the review of the manuscript. Medical writing assistance was provided by Marshall Naden on behalf of Complete HealthVizion, which was contracted and compensated by Boehringer Ingelheim.

Abbreviations

ACQ-7

Seven-question Asthma Control Questionnaire

AE

Adverse event

AUC(0–3h)

Area under the curve within 3 hours post-dosing

BMI

Body mass index

FEV1

Forced expiratory volume in 1 second

FVC

Forced vital capacity

ICS

Inhaled corticosteroids

LABA

Long-acting β2-agonist

PAQLQ(S)

Standardised Paediatric Asthma Quality of Life Questionnaire

Peak FEV1(0–3h)

Peak forced expiratory volume in 1 second within 3 hours post-dosing

PEF

Peak expiratory flow

QD

Once-daily

SD

Standard deviation

Additional file

Additional file 1: Figure S1 (124.8KB, pdf)

Enrolment, randomisation and study completion. AE, adverse event.

Footnotes

Competing interests

CV, ML-K and EH have no conflicts of interest to declare. SS is a consultant and has provided lectures for Merck Serono, has attended advisory boards and contributed to manuscript development for Genentech, has attended advisory boards and meetings for Boehringer Ingelheim, is the chair of the Pediatric Steering Committee for GlaxoSmithKline, has a grant from the University of Colorado Denver School of Medicine for a mentorship programme entitled “Building Bridges - Advancing Education by Improving Asthma Care in the Inner City”, and has contributed to the NHLBI CARE Network. PM-Z, RS and ME are employees of Boehringer Ingelheim.

Authors’ contributions

CV and SS provided input regarding study design, protocol review, results discussion, data review and manuscript development. RS contributed to the statistical analyses and manuscript development. EH was the principal investigator for study site for this trial, and was involved in discussion of study results and preparation and discussion of the manuscript. PM-Z and ME contributed to study concept, design, implementation, management and data analysis. ML-K was involved in discussion of study results, adverse events and clinical terms of adverse events. All authors read and approved the final manuscript.

Contributor Information

Christian Vogelberg, Email: christian.vogelberg@uniklinikum-dresden.de.

Petra Moroni-Zentgraf, Email: petra.moroni-zentgraf@boehringer-ingelheim.com.

Migle Leonaviciute-Klimantaviciene, Email: klimante@gmail.com.

Ralf Sigmund, Email: ralf.sigmund@boehringer-ingelheim.com.

Eckard Hamelmann, Email: eckard.hamelmann@evkb.de.

Michael Engel, Email: michael.engel@boehringer-ingelheim.com.

Stanley Szefler, Email: Stanley.Szefler@childrenscolorado.org.

References

  • 1.Papadopoulos NG, Arakawa H, Carlsen KH, Custovic A, Gern J, Lemanske R, et al. International consensus on (ICON) pediatric asthma. Allergy. 2012;67:976–997. doi: 10.1111/j.1398-9995.2012.02865.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.2011 National Health Interview Survey (NHIS) Data. 2011 Lifetime Asthma, Current Asthma, Asthma Attacks among those with Current Asthma [http://www.cdc.gov/asthma/nhis/2011/data.htm].
  • 3.Lung health in Europe: facts and figures [http://www.europeanlung.org/assets/files/en/publications/lung_health_in_europe_facts_and_figures_web_vfour.pdf].
  • 4.Liu AH, Gilsenan AW, Stanford RH, Lincourt W, Ziemiecki R, Ortega H. Status of asthma control in pediatric primary care: results from the pediatric Asthma Control Characteristics and Prevalence Survey Study (ACCESS) J Pediatr. 2010;157:276–81. doi: 10.1016/j.jpeds.2010.02.017. [DOI] [PubMed] [Google Scholar]
  • 5.Guilbert TW, Garris C, Jhingran P, Bonafede M, Tomaszewski KJ, Bonus T, et al. Asthma that is not well-controlled is associated with increased healthcare utilization and decreased quality of life. J Asthma. 2011;48:126–32. doi: 10.3109/02770903.2010.535879. [DOI] [PubMed] [Google Scholar]
  • 6.Haselkorn T, Fish JE, Zeiger RS, Szefler SJ, Miller DP, Chipps BE, et al. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol. 2009;124:895–902.e4. doi: 10.1016/j.jaci.2009.07.035. [DOI] [PubMed] [Google Scholar]
  • 7.Custovic A, Johnston SL, Pavord I, Gaga M, Fabbri L, Bel EH, et al. EAACI position statement on asthma exacerbations and severe asthma. Allergy. 2013;68:1520–31. doi: 10.1111/all.12275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Asthma’s Impact on the Nation: Data from the CDC National Asthma Control Program [http://www.cdc.gov/asthma/impacts_nation/asthmafactsheet.pdf].
  • 9.Global strategy for asthma management and prevention. Revised 2014 [http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Jun11.pdf].
  • 10.Chang C. Asthma in children and adolescents: a comprehensive approach to diagnosis and management. Clin Rev Allergy Immunol. 2012;43:98–137. doi: 10.1007/s12016-011-8261-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Desai M, Oppenheimer JJ. Medication adherence in the asthmatic child and adolescent. Curr Allergy Asthma Rep. 2011;11:454–64. doi: 10.1007/s11882-011-0227-2. [DOI] [PubMed] [Google Scholar]
  • 12.Wildhaber J, Carroll WD, Brand PL. Global impact of asthma on children and adolescents’ daily lives: the room to breathe survey. Pediatr Pulmonol. 2012;47:346–57. doi: 10.1002/ppul.21557. [DOI] [PubMed] [Google Scholar]
  • 13.Hennessy-Harstad E. Asthma and adolescents: review of strategies to improve control. J Sch Nurs. 2013;29:39–51. doi: 10.1177/1059840512454546. [DOI] [PubMed] [Google Scholar]
  • 14.Rhee H, Belyea MJ, Halterman JS. Adolescents’ perception of asthma symptoms and health care utilization. J Pediatr Health Care. 2011;25:105–13. doi: 10.1016/j.pedhc.2009.10.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Disse B, Speck GA, Rominger KL, Witek TJ, Jr, Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999;64:457–64. doi: 10.1016/S0024-3205(98)00588-8. [DOI] [PubMed] [Google Scholar]
  • 16.Sposato B, Calabrese A, Barzan R, Franco C. Comparison of the protective effect amongst anticholinergic drugs on methacholine-induced bronchoconstriction in asthma. J Asthma. 2008;45:397–401. doi: 10.1080/02770900802069125. [DOI] [PubMed] [Google Scholar]
  • 17.Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol. 2011;128:315–22. doi: 10.1016/j.jaci.2011.06.004. [DOI] [PubMed] [Google Scholar]
  • 18.Kerstjens HAM, Disse B, Schröder-Babo W, Bantje TA, Gahlemann M, Sigmund R, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol. 2011;128:308–14. doi: 10.1016/j.jaci.2011.04.039. [DOI] [PubMed] [Google Scholar]
  • 19.Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363:1715–26. doi: 10.1056/NEJMoa1008770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Kerstjens HAM, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367:1198–207. doi: 10.1056/NEJMoa1208606. [DOI] [PubMed] [Google Scholar]
  • 21.Beeh KM, Moroni-Zentgraf P, Ablinger O, Hollaenderova Z, Unseld A, Engel M, et al. Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma. Respir Res. 2014;15:61. doi: 10.1186/1465-9921-15-61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Vogelberg C, Engel M, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Downie J, et al. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study. Respir Med. 2014;108:1268–76. doi: 10.1016/j.rmed.2014.06.011. [DOI] [PubMed] [Google Scholar]
  • 23.Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1136–42. doi: 10.1164/ajrccm.161.4.9903044. [DOI] [PubMed] [Google Scholar]
  • 24.van Noord JA, Smeets JJ, Custers FLJ, Korducki L, Cornelissen PJG. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J. 2002;19:639–44. doi: 10.1183/09031936.02.00238002. [DOI] [PubMed] [Google Scholar]
  • 25.Callahan KA, Panter TM, Hall TM, Slemmons M. Peak flow monitoring in pediatric asthma management: a clinical practice column submission. J Pediatr Nurs. 2010;25:12–7. doi: 10.1016/j.pedn.2008.06.009. [DOI] [PubMed] [Google Scholar]
  • 26.Kerstjens HAM, Bleecker E, Meltzer E, Casale T, Pizzichini E, Schmidt O, et al. Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: lung function and safety [abstract 4629] Eur Respir J. 2013;42((Suppl 57)):980s–1. [Google Scholar]
  • 27.Paggiaro P, Engel M, Tudoriæ N, Forstner B, Radeczky E, Zubek V, et al. Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: design and planned analyses [abstract P4133]. Eur Respir J. 2013;42(Suppl 57).
  • 28.Beeh KM, Ablinger O, Moroni-Zentgraf P, Engel M, Hollaenderova Z, Pivovarova A, et al. Tiotropium in asthma: a dose-finding study in adult patients with moderate persistent asthma [abstract A1283]. Am J Respir Crit Care Med. 2013;187.
  • 29.Dalby R, Spallek M, Voshaar T. A review of the development of Respimat® Soft Mist™ Inhaler. Int J Pharm. 2004;283:1–9. doi: 10.1016/j.ijpharm.2004.06.018. [DOI] [PubMed] [Google Scholar]

Articles from Respiratory Research are provided here courtesy of BMC

RESOURCES